TeamDrive
RUS

Corneal inlays need a boost from eye care providers

12 January 2018

Healio

CURRENTLY VIEWING

John A. Hovanesian, MD, FACS, focuses his blog on real-world comanagement cases with valuable take-home messages. Dr. Hovanesian is a specialist in cornea, external ocular disease and refractive and cataract surgery with Harvard Eye Associates in Laguna Hills, Calif., a clinical instructor at UCLA Jules Stein Eye Institute and a member of the Primary Care Optometry 

The Raindrop corneal inlay from ReVision Optics and the AcuFocus Kamra corneal inlay have been implanted in thousands of eyes.

Ninety-five percent of patients with these devices report being quite satisfied, according to surveys, and virtually all implanting surgeons report they would recommend the procedures to their colleagues.

Personally, I have implanted corneal inlays in two close friends. One received the Raindrop about 3 years ago as part of the FDA study, and the other received the Kamra more recently. I regularly hear from both of them about how much they enjoy their freedom from glasses and their ability to be the only one at the restaurant table to read the menu without glasses.

This is an exciting time in keratorefractive surgery. We have a booming generation of millennials who are interested in this type of procedure and an even larger swelling population of presbyopic baby boomers who need near vision correction. Both the SMILE procedure (Zeiss) and these new inlays offer platforms for future development that will take us beyond the capabilities of LASIK and PRK.

But it is not enough that companies develop these technologies. Surgeons have to learn to adopt them, and optometrists must recommend them, for our science to move forward. This takes effort and investment. Adding procedures to the ophthalmologist’s skill set takes us away from our routine and tests our surgical skill, but these are very learnable procedures, building upon skills learned in LASIK. The added equipment is minimal, and the excitement generated by offering a new procedure is very good for our practices.

Most of all, these procedures are extremely gratifying. My faith in the technology that drove me to offer them to personal friends has been rewarded, and I certainly hope every eye care provider will give these new technologies a chance to improve the lives of their own patients.

Disclosure: Hovanesian reports he is a consultant for Zeiss, ReVision Optics and AcuFocus.

Source


Previous publication Next publication

Media Center

  • 19 September 2018

    Russia approves new state strategy for pharmaceutical industry

    A new state strategy for the development of the domestic pharmaceutical industry, known as "Strategy for the development of the pharmaceutical industry of Russia until 2030," has been recently approved by the Russian Ministry of Industry and Trade, with the aim to bring the Russian pharmaceutical production to a new level.

  • 18 September 2018

    The Ministry of Health of the Russian Federation improves patent protection law

    The Ministry of Health of Russia has published a notification on the development of amendments to Federal Law No. 61 of 12.04.2010 “On circulation of medicinal products”, designed to synchronize it with regulatory acts of the Eurasian Economic Union. The procedure for registration of the medicinal product will be corrected.

  • 17 September 2018

    GlobalData published new report on the Top 25 pharma companies

    The performance highlights of the Top 25 publicly traded global pharmaceutical companies by Market Cap (Mcap) for the quarter ended June 30, 2018 (Q2), compared to the quarter ended March 31, 2018 (Q1), have been analyzed in the latest research from GlobalData, a leading data and analytics company.

  • 14 September 2018

    US scientists conduct clinical trial of influenza vaccine with imiquimod

    A Phase 1 clinical trial examining whether a topical cream can enhance the immune response conferred by a “pre-pandemic” influenza vaccine is underway at Baylor College of Medicine in Houston (USA). Investigators are evaluating whether imiquimod cream, which is commonly used to treat genital warts and certain skin cancers, can boost the body’s immune response to an H5N1 influenza vaccine. The trial is enrolling 50 healthy adults ages 18-50 years. 

Read more